Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Active Biotech

3.51 SEK+0.86 %19/11 15:49
Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.86 %
+11.80 %
-31.94 %
-55.35 %
-23.80 %
-42.63 %
-83.64 %
-91.67 %
-99.15 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Read more
Market cap
92.39M SEK
Turnover
74.06K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2027

Annual report '26

6/5
2027

Interim report Q1'27

20/5
2027

General meeting '27

Third party research2026-11-11 15:08

Active Biotech: Europeisk studie går framåt - Analysguiden

Active Biotechs helägda tasquinimod-projekt testas för säkerhet och biverkningar i en fas 1b-studie på patienter med myelofibros. Efter en allvarlig biverkning i den första gruppen om tre patienter har studien fått klartecken att gå vidare till nästa...

Active Biotech
Press release2026-11-11 15:00

Analysguiden: ANALYS Active Biotech: Europeisk studie går framåt

Active Biotech
Press release2026-11-05 18:39

Redeye: Active Biotech (Q3 Review): Phase II Dose in Q1, Efficacy Data in H2 2027

Active Biotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2026-11-05 08:30

Active Biotech Interim Report Q3 2026

Active Biotech
Regulatory press release2026-11-05 08:30

Active Biotech Delårsrapport Q3 2026

Active Biotech
Press release2026-10-13 15:00

Den första kohorten enligt det uppdaterade protokollet har framgångsrikt slutfört säkerhetsutvärderingen i den kliniska HOVON 172 MF-studien av tasquinimod i myelofibros

Active Biotech
Press release2026-10-13 15:00

First cohort under amended protocol succesfully completes safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis

Active Biotech
Press release2026-09-30 11:00

Active Biotech stärker det globala patentskyddet för laquinimod genom patentbeviljande i Japan

Active Biotech
Press release2026-09-30 11:00

Active Biotech Strengthens Global Patent Protection for Laquinimod with Patent Grant in Japan

Active Biotech
Third party research2026-08-26 09:37

Active Biotech: Nytt samarbete i USA - Analysguiden

Rekryteringen av patienter till tasquinimod-studien i USA har gått trögare än väntat och bolaget breddar sin kontaktyta på denna viktiga forskningsmarknad genom ett avtal med ett stort kliniskt konsortium inom myelofibros. Den europeiska tasqunimod-studien...

Active Biotech
Press release2026-08-26 09:10

Analysguiden: ANALYS Active Biotech: Nytt samarbete i USA

Active Biotech
Press release2026-08-20 13:22

Redeye: Active Biotech (Q2 Review): Record-Deals in Myelofibrosis in 2026

Active Biotech
Regulatory press release2026-08-20 08:30

Active Biotech Interim Report Q2 2026

Active Biotech
Regulatory press release2026-08-20 08:30

Active Biotech Delårsrapport Q2 2026

Active Biotech
Press release2026-08-18 10:50

Active Biotech utökar samarbete i USA för att accelerera den kliniska utvecklingen av tasquinimod i myelofibros

Active Biotech
Press release2026-08-18 10:50

Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis

Active Biotech
Press release2026-07-24 08:30

Första patienten doserad i den uppdaterade HO172-studien med tasquinimod i myelofibros

Active Biotech
Press release2026-07-24 08:30

First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis

Active Biotech
Regulatory press release2026-06-30 08:30

Antal aktier och röster i Active Biotech

Active Biotech
Regulatory press release2026-06-30 08:30

Number of shares and votes in Active Biotech

Active Biotech